

Sterol Regulatory Element Binding Proteins (SREBPs)

Jenny Young *, Cherng Shen **, Ma Hongbao ***

* New Start Company, Brooklyn, New York 11212, USA, youngjenny2008@yahoo.com, 347-321-7172

** Department of Electrical Engineering, Chengshiu University, Niasong, Taiwan 833, China, cherngs@csu.edu.tw; 011886-7731-0606 ext 3423

*** Bioengineering Department, Zhengzhou University, Zhengzhou, Henan 450001, China, mahongbao2007@gmail.com, 347-321-7172

Abstract: Sterol regulatory element binding proteins (SREBPs) are transcription factors that bind to the sterol regulatory element DNA sequence TCACNCCAC. SREBPs belong to the basic-helix-loop-helix leucine zipper class of transcription factors. Unactivated SREBPs are attached to the nuclear envelope and endoplasmic reticulum membranes. In cells with low levels of sterols, SREBPs are cleaved to a water soluble N-terminal domain which is translocated to the nucleus. These activated SREBPs then bind to specific sterol regulatory element DNA sequences which upregulate the synthesis of enzymes involved in sterol biosynthesis. Sterols in turn inhibit the cleavage of SREBPs and therefore synthesis of additional sterols is reduced through a negative feed back loop. [The Journal of American Science. 2008;4(2):88-94]. (ISSN 1545-1003).

Keywords: sterol regulatory element binding proteins (SREBPs); transcription factor; endoplasmic reticulum membrane

1. Introduction

Sterol regulatory element binding proteins (SREBPs) are transcription factors that bind to the sterol regulatory element DNA sequence TCACNCCAC (Chen, Chen et al. 2006; Rasmussen, Blobaum et al. 2008). SREBPs belong to the basic-helix-loop-helix leucine zipper class of transcription factors (Brown and Goldstein 1997). Unactivated SREBPs are attached to the nuclear envelope and endoplasmic reticulum membranes (Sakai, Nohturfft et al. 1997). In cells with low levels of sterols, SREBPs are cleaved to a water soluble N-terminal domain which is translocated to the nucleus (Zhang, Shin et al. 2005). These activated SREBPs then bind to specific sterol regulatory element DNA sequences which upregulate the synthesis of enzymes involved in sterol biosynthesis (Yokoyama, Wang et al. 1993; Wang, Sato et al. 1994). Sterols in turn inhibit the cleavage of SREBPs and therefore synthesis of additional sterols is reduced through a negative feed back loop (Wikipedia, 2008).

Beginning with the discovery of the SREBPs in 1993, a productive combination of biochemistry, molecular biology and genetics, has brought to light the complex mechanisms by which animal cells maintain the proper levels of intracellular lipid (fats and oils) in the face of widely varying circumstances (lipid homeostasis) (Brown and Goldstein 1999; Brown, Ye et al. 2000). These studies exposed a signaling mechanism of beguiling complexity that is responsible for the end-product feedback regulation of gene transcription. For example, when cellular cholesterol levels fall below the level needed, the cell makes more of the enzymes necessary to make cholesterol. A principal step in this response is to make more of the mRNA transcripts that direct the synthesis of these enzymes. Conversely, when there is enough cholesterol around, the cell stops making those mRNAs and the level of the enzymes falls. As a result, the cell quits making cholesterol once it has enough.

The defining feature of the SREBP pathway is the proteolytic release of a membrane-bound transcription factor, SREBP. Proteolytic cleavage frees it to move through the cytoplasm to the nucleus. Once in the nucleus, SREBP can bind to specific DNA sequences that are found in the control regions of the genes that encode enzymes needed to make lipids. This binding to DNA leads to the increased transcription of the target genes.

The ~120 kDa SREBP precursor protein is anchored in the membranes of the endoplasmic reticulum and nuclear envelope by virtue of two membrane-spanning helices in the middle of the protein. The precursor has a hairpin orientation in the membrane, so that both the amino-terminal transcription factor domain and the COOH-terminal regulatory domain face the cytoplasm. The two membrane-spanning

helices are separated by a loop of about 30 amino acids that lies in the lumen of the *endoplasmic reticulum*. Two separate, site-specific proteolytic cleavages are necessary for release of the transcriptionally active amino-terminal domain. Regulation of SREBP cleavage employs a notable feature of eukaryotic cells, subcellular compartmentalization defined by intracellular membranes, to ensure that cleavage occurs only when needed.

2. SREBP-1 and SREBP-2

The mammalian gene for SREBP-1 contains two promoters that control the production of two proteins, SREBP-1a and -1c, and each contains a unique N-terminal transcriptional activation domain, but they are otherwise identical. The relative level of each mRNA varies from tissue to tissue and they respond differently to regulatory stimuli. SREBP-1c is more abundantly expressed in liver, where its level is also regulated by insulin and liver X receptor activators, and it is also autoregulated by SREBPs. In contrast, SREBP-1a mRNA levels are relatively low and constant in different tissues and few studies have specifically analysed its pattern of expression and regulation. According to the studies by Zhang and Shin, the promoter for SREBP-1a is contained in a very small promoter-proximal region containing two Sp1 sites. The small and relatively simple structure for its promoter provides an explanation for the low level of SREBP-1a expression. Additionally, since Sp1 has been implicated in the modest regulation of several genes by insulin, its involvement in the expression of the SREBP-1a promoter provides an explanation for the modest insulin regulation observed in animal experiments (Zhang, Shin et al. 2005). SREBP-2 regulates the genes of cholesterol metabolism.

SREBP-1a is a unique membrane-bound transcription factor highly expressed in actively growing cells and involved in the biosynthesis of cholesterol, fatty acids, and phospholipids. Because mammalian cells need to synthesize membrane lipids for cell replication, the functional relevance of SREBP-1a in cell proliferation has been considered a biological adaptation (Nakakuki, Shimano et al. 2007).

The 5' end of the mRNA-encoding SREBP-1 exists in two forms, designated 1a and 1c. The divergence results from the use of two transcription start sites that produce two separate 5' exons, each of which is spliced to a common exon 2. Mutations in the sterol regulatory element binding protein gene (SREBF)-1 may contribute to insulin resistance states. However, the variants described to date do not affect the SREBP function (Vernia, Eberle et al. 2006).

3. SREBP and diabetes

Diabetic renal disease is associated with lipid deposits in the kidney. In 2002, Sun et al made the study to determine whether there is altered regulation of the sterol regulatory element-binding proteins (SREBPs) in the diabetic kidney and whether SREBPs mediate the abnormal renal lipid metabolism and diabetic renal disease. In streptozotocin-induced diabetes in the rat, there were marked increases in SREBP-1 and fatty acid synthase (FAS) expression, resulting in increased triglyceride (TG) accumulation. Treatment of diabetic rats with insulin prevented the increased renal expression of SREBP-1 and the accumulation of TG. The role of hyperglycemia in the up-regulation of SREBP-1 was confirmed in renal cells cultured in a high glucose media. High glucose induced increased expression of SREBP-1a and -1c mRNA, SREBP-1 protein, and FAS, resulting in increased TG content. To determine a direct role for SREBP in mediating the increase in renal lipids and glomerulosclerosis, they studied SREBP-1a transgenic mice with increased renal expression of SREBP-1. The increase in SREBP-1 was associated with increased expression of FAS and acetyl CoA carboxylase, resulting in increased TG content, increased expression of transforming growth factor beta1 and vascular endothelial growth factor, mesangial expansion, glomerulosclerosis, and proteinuria. Their study therefore indicates that renal SREBP-1 expression is increased in diabetes and that SREBP-1 plays an important role in the increased lipid synthesis, TG accumulation, mesangial expansion, glomerulosclerosis, and proteinuria by increasing the expression of transforming growth factor beta and vascular endothelial growth factor (Sun, Halaihel et al. 2002).

SREBP-1c is intimately involved in the regulation of lipid and glucose metabolism and SREBP-1c gene might influence diabetes risk and plasma cholesterol level (Laudes, Barroso et al. 2004).

ABC transporter A1 (ABCA1) mediates and rate-limits biogenesis of high density lipoprotein (HDL), and hepatic ABCA1 plays a major role in regulating plasma HDL levels. HDL generation is also responsible for release of cellular cholesterol. In peripheral cells ABCA1 is up-regulated by the liver X receptor (LXR) system when cell cholesterol increases. However, cholesterol feeding has failed to show a significant increase in hepatic ABCA1 gene expression, and its expression is up-regulated by statins (3-hydroxy-3-methylglutaryl-CoA reductase inhibitors), suggesting distinct regulation. Compactin activated the

novel liver-type promoter in rat hepatoma McARH7777 cells by binding SREBP-2. In contrast, compactin repressed the previously identified peripheral-type promoter in an LXR-responsive element-dependent but not E-box-dependent manner. Thus, compactin increased the liver-type transcript and decreased the peripheral-type transcript. The same two transcripts were also dominant in human and mouse livers, whereas the intestine contains only the peripheral-type transcript. Treatment of rats with pravastatin and a bile acid binding resin (colestimide), which is known to activate SREBP-2 in the liver, caused a reduction in the hepatic cholesterol level and the same differential responses in vivo, leading to increases in hepatic ABCA1 mRNA and protein and plasma HDL levels. The dual promoter system driven by SREBP-2 and LXR regulates hepatic ABCA1 expression and may mediate the unique response of hepatic ABCA1 gene expression to cellular cholesterol status (Tamehiro, Shigemoto-Mogami et al. 2007).

4. SREBP protein and gene structure

(1) Human SREBP1 protein sequence (Olsen, Blagoev et al. 2006):

```
1 mdeppfseaa leqalgepcd ldaalltdie dmlqlinnqd sdfpglfdpp yagsgaggtg
61 paspdtsspg slspppats sseafslgp qaapsplspp qpaptplkmy psmpafspgp
121 gikeesvpls ilqtptpqp plgallpqsfp apappqfsst pvlgypppg gfstgsppgn
181 tqqlplglpl asppgvppvs lhtqvsvvp qlltvtvaap taapvtttvt sqiqvvpvl
241 qphfikadsl lltamktgga tvkaaglspl vsgttvqtgp lptlvsggti latvplvda
301 eklpinrlaa gskapasaqs rgekrtaha iekryrssin dkielkdlv vgteaklnks
361 avlrkaidyi rflqhsnqkl kqenlsrta vhskslkdvl vsacsgsgnt dvlmegvkte
421 vedtlppps dagspfqssp slsgrgsgs ggsgsdsepd spvfedskak peqrpslhr
481 gmldrslal ctvlflcsc nplaslgar glpspsdttv vyhspgrnvl gtesrdpgpw
541 aqwlppvvw lllglvsvs lvllfygep vtrphspgav yfwrhrkqad ldlargdfaq
601 aaqqlwlalr algrplptsh ldlacslwn lirlhllrlw vgrwlagrag glqqdcalrv
661 dasasardaa lvykhqlh tmgkhtgghl tatnlalsal nlaecagdav svatlaeiyy
721 aaalrvktsl pralhfltrf flssarqacl aqsgsvppam qwlchpvgvr ffdgdwsvl
781 stpweslysl agnpvdplaq vtqlfrehll eralncvtqp npspgsadgd kefsdalgy
841 qllnscsdaa gapaysfsis ssmattgvd pvakwwaslt avvihwlrrd eaaerlclp
901 vehlprvlqe serplpraal hsfkaarall gcakaesgpa slticekasg yldslattp
961 assidkavq lflcdlllv rtslwrqqqp papapaaqt ssrpqasale lrgfqrldss
1021 lrrlaqsfrp amrvflhea tarlmagasp trthqlldrs lrragpggk ggavaepr
1081 ptrrehaeal llascylppg flsapqrv mlaeaartle klgdrllhd cqqlmlrlgg
1141 gttvtss
```

(2) Human SREBP2 protein sequence (Sjoblom, Jones et al. 2006):

```
1 mddsgelggl etmettelg deltdgide mlqfvsnqvg efdlfeql cssfpgsggs
61 gsssgsgss ssssnrgss sgavdpsvqr sftqvtpsf spsaaspqap tlqkvkspts
121 vptpratpi lqprpqpqp pqtqlqqtv mitptfstop qtriiqpli yqnaatsfqv
181 lqpqvqslvt ssqvqvvtiq qqvqvqqr vltqtangtl qlapatvqt vaapqvqqvp
241 vlvqqqiikt dslvltlkt dgsppvmaavq npaltatp iqtaalqvpt lvgssgtitl
301 tmpvmmgqek vpikqvpggv kqleppkege rrtthniek ryrssindki ielkdvlmgt
361 dakmhksgvl rkaidyikyl qqvnhklrge nmvlklnqk nkllkgidlg slvdnevdik
421 iedfnqnvll mspasdsqs qagfypsids sepgspldd akvkdepdp pvalgmvdrs
481 rillevltfl clsnpltsl lqwgahdsd qhphsgsgrs vlsfsgsgg wfdwmmptll
541 lwlvngvivil svfvkllvhg epvirphrs svtfwrhrkq adldlargdf aaaagnlqtc
601 lavlgralpt srlldacsls wnviryslqk lrlvrwllkk vfqcratpa teagfedea
661 tsardaalay hrlhqlhitg klpagsacsd vhmalcavn l aecaekipp stlveihlta
721 amglktregg klglfasyfl sraqslcpe hsavpdsrlw lchplgqkff merswsvksa
781 akelycaqr npadpiaqv qafcknller aieslvkppa kkkagdqeee scfssaley
841 kllhsfvds vgvmsplsr ssvlksalgp diicrwwtsa itvaiswlgg ddaavrshft
901 kveripkale vtesplv kai fhacramhas lpgkadgqqs sfchcerasg hlwsslnvsg
961 atsdpalnhv vqltcdlll slrtalwqkq asasqavget yhasgaelag fqrldgslr
1021 lahsfrpayr kvflheatvr lmagasprt hqllhslrr rttqstkhge vdawpgqrer
1081 atailacrhl lplslfsspg qravllaea rtlekvgdrr scndcqqmiv klggtaiaa
1141 s
```

(3) Human SREBP1 gene sequence (Furuta, Pai et al. 2008):

1 agcagagctg cggccggggg aaccagttt ccgaggaact ttccgccgc gccggggccg
61 ctctgaggcc agggcaggac acgaacgcgc ggagcggcgg cggcgactga gagccggggc
121 cgcggcggcg ctcctagga agggccgtac gagcggcggg gcccggcggg cctcccggag
181 gagcggctg cgccatggac gagccacct tcagcaggc ggctttggag caggcgtgg
241 gcgagccgtg cgatctggac gcggcgtgc tgaccgacat cgaagacatg cttcagctta
301 tcaacaacca agacagtac ttccctggcc tatttgacc accctatgct gggagtggg
361 cagggggcac agacctgcc agccccgata ccagctcccc aggcagcttg tctccactc
421 ctgccacatt gagctcctct cttgaagcct tctgagcgg gccgcaggca gcgcctcac
481 cctgtcccc tcccagcct geaccactc cattgaagat gtaccgtcc atgcccgtt
541 tetcccctgg gcttggatc aaggaagagt cagtccact gagcatctg cagacccca
601 cccacagcc cctgccagg gcctcctgc cacagactt cccagccca gcccaccgc
661 agttcagtc caccctgtg ttaggctacc ccagcctcc gggaggctt tctacaggaa
721 gcctcccgg gaacaccag cagccgtgc ctggcctcc actggttcc ccgccaggg
781 tcccctcct cctcttgc accaggtcc agagtgtgt cccccagc ctactgacg
841 tcacagctc ccccagcca gccctgtaa cgaccactg gacctgcag atccagcag
901 tcccgtcct gctgcagcc cacttcatca aggcagactc gctgcttct acagccatga
961 agcagacgg agccactgt aaggcggcag gtctcagtc cctgttctt ggcaccactg
1021 tgcagacagg ccctttgcc accctgtga gtggcggaa catcttggca acagtccac
1081 tggctgtaga tgcggagaag ctgcctatca accggctcgc agctggcagc aaggccccg
1141 cctctgcca gagcgtgga gagaagcga cagccacaa gcctattgag aagcgtacc
1201 gctctccat caatgacaaa atcattgagc tcaaggatct ggtgtgggc actgagcaa
1261 agctgaataa atctgctgc ttgcgaagg ccatcgacta cattgcttt ctgcaacaa
1321 gcaaccagaa actcaagcag gagaacctaa gtctgcgac tgctgtccac aaaagcaat
1381 ctctgaagga tctgtgtgc gcctgtgga gtggaggga cacagacgtg ctcattgagg
1441 gcgtgaagac tgagtgagg gacacactga cccccccc ctggatgct ggctcacct
1501 tccagagcag ccccttgc ctggcagca ggggcagtgg cagcggggc agtggcagt
1561 actcggagcc tgacagcca gtctttagg acagcaaggc aaagccagag cagcggcct
1621 ctctgcacag cggggcatg ctggaccgt cccgcctggc cctgtgcag ctcttctc
1681 tctgctgtc ctgcaacccc ttggcctct tctgggggc ccgggggctt cccagccc
1741 cagataccac cagcgttac catagcccgt ggcgcaact gctgggcacc gagagcag
1801 atggccctgg ctgggccag tggctgctgc cccagtggt ctggctgctc aatgggctg
1861 tgggtctgt ctcctgtg ctctctttg tctacgtga gccagtaca cggccccact
1921 caggccccgc cgtgtactt tggaggcatc gcaagcaggc gtacctggac ctggccccg
1981 gagactttgc ccaggctgc cagcagctgt ggctggcctt ggggcactg ggccggccc
2041 tgcacaccc ccaactggac ctgcttga gcctcctct gaacctc cgtcaactgc
2101 tgcagcgtc ctgggtgggc cgtggctgg cagcggggc agggggcctg cagcaggat
2161 gtgctctgc agtgatgct agcggcagc cccgagacgc agccctggtc taccataag
2221 tgcaccagt gcacacatg gggagcaca cagcgggca cctactgcc accaactgg
2281 cgtgagtgc cctgaacctg gcagagtgt caggggatg cgtgtctgt gcgacgtgg
2341 ccgagatcta tttggcggct gcattgagag tgaagaccag tctccacgg gccttgcatt
2401 ttctgacac cttctcctg agcagtgcc gccaggcctg cctggcacag agtggctcag
2461 tgcctcctgc catgcagtgg ctctgccacc ccgtgggcca ccgttctt gtgatggg
2521 actggtccgt gctcagtacc ccatgggaga gcctgtacag cttggccggg aaccagtg
2581 acccctggc ccagtgact cagctattc gggaactct ctagagcga gactgaact
2641 gtgtaccca gccaacccc agccctgggt cagctgatg ggacaaggaa ttctggatg
2701 cctcgggta cctgcagct ctgaacagct gttctgatg tgcggggct cctgctaca
2761 gcttccat cagtccage atggccaca ccaccggct agaccgggt gccaagtgt
2821 gggcctct gacagctgt gtatccact ggctgcggc ggatgaggag gcgctgagc
2881 ggctgtccc gctgtggag cacctgccc ggtgtctga ggagtctg agaccctgc
2941 ccagggcagc tctgactcc tcaagctg cccggccct cctgggctgt gccaaggcag
3001 agtctgtcc agccagcct accatctgt agaaggccag tgggtacct caggacagc
3061 tggctaccac accagccag agctccattg acaaggcct gcagctgtc ctgtgtgac
3121 tcttctgt ggtgcgacc agcctgtgg gccagcagca gccccggc ccggccccg
3181 cagcccagg caccagcag agccccag cttccgctt tagctgct gcttccaac
3241 gggacctgag cagcctgag cggctggcac agagctccg gcccgccatg cggagggtg

3301 tctacatga ggccacggcc cggctgatgg cgggggcccag cccacacgg acacaccagc
3361 tctcgaccg cagtctgagg cggcgggag gccccgggtg caaaggaggc gcggtggcgg
3421 agctggagcc gcggcccac cggcgggagc acgcggaggc cttgctgctg gcctcctgct
3481 acctgcccc cggcttctg tcggcggccc ggcagcgcgt gggcatgctg gctgaggcgg
3541 cgcgcacact cgagaagctt ggcgatgcc ggctgctgca cgaactgca cagatgctca
3601 tgcgctggg cgggtggacc actgtcactt ccagctagac cccgtgtccc cggcctcagc
3661 acccctgtct ctaggcaactt tggctcccgt cagcttctgt cctgcgtcga agctttgaag
3721 gccgaaggca gtgcaagaga ctctggcctc cacagtcca cctgcggctg ctgtgtgcct
3781 tcgcggtgga aggcccgagg ggcgcatct tgaccctaag accggcggcc atgatgtgc
3841 tgacctctgg tggccgatc gggcactgca gggcccgagc cattttgggg ggccccctc
3901 cttgctctgc aggcacctta gtggctttt tctcctctgt tacagggaag agagggttac
3961 atttcctgt gctgacggaa gccaaactgg ctttcccga ctgcaagcag ggctctgcc
4021 cagaggcctc tctcctcgtc ggggagaga gacgtgtaca tagttaggt cagcgtgctt
4081 agcctcctga cctgaggctc ctgtgctact ttgcttttg caaactttat ttcatagat
4141 tgagaagttt tgtacagaga attaaaaatg aaattatita taactggaa aaaa

(4) Human SREBP2 gene sequence (Lee and Kong 2007):

1 gccctttctg tgcggcgccc gggcgcaacg caaacatggc ggcgggtggc acccgtcgtt
61 gagggcgtgc cggcgggggg ttgtcgggtg tcatggggcg tggcgacggc accgccccg
121 cgtctccctg agcgggacgg cagggggggc ttctgcgctg agccgggca tggacgacag
181 cggcgagctg ggtggtctgg agaccatgga gaccctcag gagctggcg acgagctgac
241 cctgggagac atcgacgaga tctgcaatt tctcagtaat caagtggag agttccctga
301 cttgtttca gaacagctgt gtagctcctt tctggcagt ggtgtagtg gtagcagcag
361 cggcagcagt ggcagcagca gcagcagcag caatggcagg ggcagcagca gcggagctgt
421 ggaccctca gtgcaacggc cttcaccga ggtcacatta cttccttct ctccctcggc
481 ggctcccca caggctcaa ctctgcaagt caagtttct cccacctcag tcccaccac
541 accagggca actcctatc ttagccccg ccccagccc cagcctaac ctcaaactca
601 gctgcaaaa cagacgtaa tgatcacgc aacattcagc accactccgc agacaggat
661 catcagcag cttttgat accagaatgc agctactagc ttcaagtc ttagcctca
721 agtccaaagc ctggtgacat cctcccagg acagccggc accattcagc agcaggtgca
781 gacagtacag gccagcggg tgctgacaca aacggccaat ggcacgctgc agaccctgc
841 cccggctacg gtgcagacag ttgctgccc acaggtgagc caggtcccgg tctgtgcca
901 gcctcagatc atcaagacag attccctgt tttgaccaca ctgaagacag atggcagccc
961 tttatgctc ggggtccaga accggccct caccgccc accaccctca tccagcggc
1021 tgccctcaa gtaccaacc tgggtggcag cagtgggacc attctgacca caatgcctgt
1081 aatgatggg caagagaaa tgcccataa gcaggtacct gggggagta agcagctga
1141 gcccccaaa gaaggagaaa ggcggacaac ccataatc attgagaaa gatcgtc
1201 ctccatcaat gacaaaata tgaattgaa agactggtc atggggacag acgcaagat
1261 gcacaagtct ggcgttctga ggaaggccat tgattacac aaatactgc agcaggtca
1321 tcataaactg ccagggaga acatggtgct gaagctggca aatcaaaaga acaagctct
1381 aaaggcctc gacctaggca gtctggtgga caatgaggtg gacctgaaga tcgaggactt
1441 taatcagaat gctcttctga tgcctccc agcctctgac tcagggtccc agcgtgctt
1501 ctctccctac tccattgact ctgagccagg aagccctcta ttgatgatg caaaggtcaa
1561 agatgagcca gactctctc ctgtggcgt gggcatggtg gaccgctcac ggattctct
1621 gtgtgtctc acctctctg ccctctctt taaccctc acttccctgc tgcagtggg
1681 aggggcccac gactctgacc agcaccaca ctgagctct ggcgcagtg tctgtcatt
1741 cgagttagt tctgggggct ggtttgactg gatgatgct actctctct tatggtggt
1801 aatggtgtg atgtctctga gcgtcttct gaagctgctg gttcatggg agccagtgt
1861 ccggccacac tgcgctctc cgttcacct ctggaggcac cggaaacagg cagatctgga
1921 tctgccaga ggagatttg cagctgctc cggcaaccta caaactgcc tggcagttt
1981 gggccgggca ctgccacct cccgctgga cctggcctgc agcctctct ggaactgtat
2041 ccgctacagc ctgcagaagc tacgctggt gcgctgctc ctcaagaaag tctccagtg
2101 ccggcgggccc acgcccagca ctgaggcagg ctttgaagac gaagctaaga ccagcggccc
2161 ggatcggct ctggcctatc accggctgca ccagctgac atcacaggga agcttctgc
2221 aggatccgcc tgttccgatg tacacatggc gttgtgtgcc gtgaacctgg ctgaatgtc
2281 agaggagaag atcccaccga gcacactggt tgatccat ctgactgct ccatggggct

2341 caagaccgg tgtggaggca agctgggctt cctggccagc tacttctca gccgagcca
2401 gagcctgtgt ggccccgagc acagtgtgt tctgactcc ctgcctggc tctgccacc
2461 cctgggccag aagttttca tggagcggag ctggtctgtg aagtcagctg ccaaggagag
2521 tctatactgt gccagagga acccagctga cccattgcg caggtccacc aggcctctg
2581 caagaacctg ctggagcgag ctatagagtc ctggtgaaa cctcaggcca agaagaaggc
2641 tggagaccag gaagaagaga gctgtgaatt ctccagtct ctggagtact tgaattact
2701 tcattctttt gtgactctg tgggggttat gagccccca ctctccagga gctcctgct
2761 caagtccgcc ctgggtccag acatcatctg tcggtggtgg acgtctgcaa tcactgtggc
2821 catcagctgg ctccaggag acgatgcagc tgtgcctct cattttacca aagtgaacg
2881 catccccaa gcccctggaag tgacagagag ccccctggtg aagccatct tccatgctg
2941 cagagccatg catgcctcac tcctgggaa agcagatggg cagcagagtt ccttctgcca
3001 ttggagagg gccagtggc acctatggag cagcctaac gtcagtggg ccacctctga
3061 cctgcccctc aaccacgtg tccagtctc cacctgtgac ctgctactgt cgctacggac
3121 agcgtctgg caaaaacagg ccagtggcag ccaggctgtg ggggagacct accacgcgtc
3181 aggcgtgaa ctggcgggct tccaacggga cctgggcagc ctgctcaggc tggcacacag
3241 ctccgccca gcataccgca aggtgttct gcataagcc accgtgccc tgatggcagg
3301 agccagccc acccgacc acccagctct ggaacacagc ctgctggcggc gcaccagca
3361 gagcaccaag cacggagagg tggatgcctg gcccgccag cgagagcggg ccaccgcat
3421 cctgctggcc tgccgccacc tgcccctc ctctctcc tccccggcc agcgggcagt
3481 gctgctggcc gaagctgcc gcaccctgga gaagtgggc gaccggcgt cctgcaacga
3541 ctgccagcag atgattgta agctgggtg tggcactgcc attgccct cctgaccacc
3601 aggctcagcc caccctcca cctctctc gatttctc tctcccc agcatctcc
3661 cgctgagagt ggtggggaag agcctgtct tcttagctgt cacctgccga ggcttctggg
3721 ccaactcagg cagtgcacc ctggcagag cccctaaag ctgctgtcac tagatgcca
3781 tggtcaggg cctgtgggc gtgagaggat agtgggcagg gcagaaactg ggcagccctg
3841 actgatagc agcaggggga gctccaagc tgccaagcc ctgctccag ccttctgag
3901 tttctctc ctgaacccta ctctctct tttgctct cagttttat caggcttct
3961 ctgggggaca gcagtctct agcaccagg agcagttgcc ctcaggcctg tgcccagcat
4021 gccctccc tttatagca atgtttcta ccagtgtct tgggttgc atgatgcgag
4081 gctgagttgc ttagcgtct gatttctc cctgggtct cgttccctc cctgggcctg
4141 actgagcctg ctattgtt tcccttat tacacaggac agccagggga ggagggggg
4201 ccagccctgg gaggtggtg ggaggcagg gcaggcctg cggatgatg aaataatgt
4261 ggcatattt ttaatttt taaaaataa atggtatct atttaaaaa aaaaaaaaa
4321 aaaaa

References

- Wikipedia (2008). sterol regulatory element binding protein. http://en.wikipedia.org/wiki/Sterol_regulatory_element_binding_protein.
- Brown, M. S. and J. L. Goldstein (1997). "The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor." *Cell* **89**(3): 331-40.
- Brown, M. S. and J. L. Goldstein (1999). "A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood." *Proc Natl Acad Sci U S A* **96**(20): 11041-8.
- Brown, M. S., J. Ye, et al. (2000). "Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans." *Cell* **100**(4): 391-8.
- Chen, M., L. M. Chen, et al. (2006). "Androgen regulation of prostatic gene expression is mediated by sterol-regulatory element-binding proteins and SLUG." *Prostate* **66**(9): 911-20.
- Furuta, E., S. K. Pai, et al. (2008). "Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1." *Cancer Res* **68**(4): 1003-11.
- Laudes, M., I. Barroso, et al. (2004). "Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes." *Diabetes* **53**(3): 842-6.
- Lee, C. and M. Kong (2007). "An interactive association of common sequence variants in the neuropeptide Y gene with susceptibility to ischemic stroke." *Stroke* **38**(10): 2663-9.
- Nakakuki, M., H. Shimano, et al. (2007). "A transcription factor of lipid synthesis, sterol regulatory element-binding protein (SREBP)-1a causes G(1) cell-cycle arrest after accumulation of cyclin-dependent kinase (cdk) inhibitors." *Febs J* **274**(17): 4440-52.

- Olsen, J. V., B. Blagoev, et al. (2006). "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." *Cell* **127**(3): 635-48.
- Rasmussen, H. E., K. R. Blobaum, et al. (2008). "Lipid extract of *Nostoc commune* var. *sphaeroides* Kutzinger, a blue-green alga, inhibits the activation of sterol regulatory element binding proteins in HepG2 cells." *J Nutr* **138**(3): 476-81.
- Sakai, J., A. Nohturfft, et al. (1997). "Identification of complexes between the COOH-terminal domains of sterol regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating protein." *J Biol Chem* **272**(32): 20213-21.
- Sjoblom, T., S. Jones, et al. (2006). "The consensus coding sequences of human breast and colorectal cancers." *Science* **314**(5797): 268-74.
- Sun, L., N. Halaihel, et al. (2002). "Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus." *J Biol Chem* **277**(21): 18919-27.
- Tamehiro, N., Y. Shigemoto-Mogami, et al. (2007). "Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status." *J Biol Chem* **282**(29): 21090-9.
- Vernia, S., D. Eberle, et al. (2006). "A rare missense mutation in a type 2 diabetes patient decreases the transcriptional activity of human sterol regulatory element binding protein-1." *Hum Mutat* **27**(2): 212.
- Wang, X., R. Sato, et al. (1994). "SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis." *Cell* **77**(1): 53-62.
- Yokoyama, C., X. Wang, et al. (1993). "SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene." *Cell* **75**(1): 187-97.
- Zhang, C., D. J. Shin, et al. (2005). "A simple promoter containing two Sp1 sites controls the expression of sterol-regulatory-element-binding protein 1a (SREBP-1a)." *Biochem J* **386**(Pt 1): 161-8.